latest news releases from the newsroom
Annual General Meeting of Shareholders in Securitas AB (publ)
STOCKHOLM, Sweden, March 10, 2003 (PRIMEZONE) -- The shareholders in Securitas AB (Other OTC:SCTBF) are hereby invited to attend the Annual General Meeting to be held at 5 p.m. on Tuesday, April 8, 2003, in "Vintertradgarden" at the Grand Hotel, entry via "Royal entre", Stallgatan 6. Registration for the General Meeting begins at 4:15 p.m.
Teleca Appoints New CFO
MALMO, Sweden, March 10, 2003 (PRIMEZONE) -- Teleca today announced the appointment of Andreas Zartmann as new Chief Financial Officer effective from 7 May 2003.
Gyros AB and Kratos Analytical Collaboration a Success
UPPSALA, Sweden, March 10, 2003 (PRIMEZONE) -- Gyros AB today announced the success of their collaboration with Kratos Analytical, begun in May 2002. Users of the Axima-QIT(TM) and Axima-CFR(TM) plus line of mass spectrometry workstations will soon be able to benefit from using Gyrolab(TM) MALDI for sample preparation prior to analysis.
ReadSoft captures CeBIT and AIIM
STOCKHOLM, March 10, 2003 (PRIMEZONE) -- In March and April, ReadSoft will be showing off the latest innovations within automatic document capture at two important IT-exhibitions. First in line is the largest technology show in the world, CeBIT in Hanover. A couple of weeks later, ReadSoft goes to the American document management exhibition AIIM, this year arranged in New York City.
Frontline: Share Acquisition
HAMILTON, Bermuda, March 10, 2003 (PRIMEZONE) -- One employee of Frontline (NYSE:FRO) has exercised options to acquire a total of 10,000 shares in Frontline. All shares have been acquired at a strike price of NOK 28.66 per share. Total proceeds were NOK 286,600.
Basilea Pharmaceutica Ltd
FDA Fast Track Designation for Basilea's Novel Broad Spectrum Antibiotic
BASEL, Switzerland, March, 10, 2003 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. today announced that it has received fast track designation from the U.S. Food and Drug Administration (FDA) for its novel broad-spectrum cephalosporin antibiotic BAL5788, for the treatment of complicated skin and skin structure infections (cSSSI). Fast track designation is designed to expedite the availability of treatments that address unmet medical needs for serious and life-threatening diseases.